A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC). This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback